期刊文献+

倍他乐克联合参松养心胶囊对阵发性房颤患者P波离散度的影响 被引量:10

Therapeutic effects of betaloc combined with Shensongyangxin capsule on P wave dispersion in patients with paroxysmal atrial fibrillation
下载PDF
导出
摘要 目的探讨倍他乐克及参松养心胶囊对阵发性房颤(PAF)患者P波离散度(Pd)的影响。方法将167例PAF患者作为房颤组,随机分为3亚组:A组(倍他乐克组)、B组(参松养心胶囊组)、C组(两药均用组)。以50例无房颤者作为对照组。比较房颤组及无房颤组以及3亚组间治疗前、后Pd水平的差异。结果房颤组Pd高于无房颤组(P<0.01),治疗前A、B、C3亚组Pd差异无显著意义(P>0.05),A、B、C3亚组治疗后Pd较治疗前均有显著降低,差异有显著意义(P<0.05或P<0.01),治疗后A、B亚组间Pd差异无显著意义(P>0.05),C亚组Pd明显低于A、B亚组(P<0.01)。结论倍他乐克、参松养心胶囊联用更有助于预防房颤的复发。 Objective To investigate the therapeutic effects of betalec combined with Shensengyangxin capsule on P wave dispersion (Pd) in patients with paroxysmal atrial fibrillation (PAF). Methods 167 patients whth PAF were divided into 3 groups randomly, group A ( betaloc group), group B ( Shensengyangxin capsule group) and group C(beth drugs group),and 50 healthy subjects were chosen as control group. Results The Pd in PAF groups was significantly higher than that of control group ( P 〈 0.01 ). There was no significant differences in Pd among three PAF groups ( P 〉 0.05 ). The Pd in three PAF groups was obviously decreased after treatment, compared with that before treatment ( P 〈 0.05 or P 〈 0.01) .There was no significant difference in Pd after treatment between group A and group B ( P 〉 0.05) ,however, which in group C was significantly lower than that of group A and group B ( P 〈 0. 01 ). Conclusion Betaloc combined with Shensongyangxin capsule is helpful to prevent the recurrence of PAF.
出处 《疑难病杂志》 CAS 2007年第5期270-272,共3页 Chinese Journal of Difficult and Complicated Cases
关键词 房颤 阵发性 倍他乐克 参松养心胶囊 心电图 Atrial fibrillation, paroxysmal Betaloc Shensongyangxin capsule Electrocardiogram
  • 相关文献

参考文献5

二级参考文献14

  • 1曲秀芬,黄永麟,纪树彦,朴晶艳,宋丽云.β受体阻滞剂对急性心肌梗死心率变异性和预后的影响(摘要)[J].临床心电学杂志,1995,4(4):168-169. 被引量:13
  • 2吴以岭.“脉络—血管系统病”新概念及其治疗探讨[J].疑难病杂志,2005,4(5):285-287. 被引量:240
  • 3Morganroth J.Risk factor for the development of proarrythmic events[J].Am J Cardiol,1987,321:406-412.
  • 4The Cardiac Arrhythmia Supperssion Trial (CAST) Investigators.Preliminary report:effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction [ J ].N Engl J Med,1998,321 (6):406-412.
  • 5Report of the joint International Society and Federation of Cardiology World Health Organization Task Force on Standardization of Clinical Nomenclature.Nomenclature and criteria for diagnosis of ischemia heart disease.Circulation,1979,59:607-609.
  • 6Casolo GC,Stroder P,Signorini C,et al.Heart rate variability during the acute phase of myocardial infarction.Circulation,1992,85:2 073-2 079.
  • 7Voss A,Hnatkova K,Wessel N,et al.Multiparametric analysis of heart rate variability used for risk stratification among survivors of acute myocardial infaction.Pacing Clin Electronphysiol,1998,21(1 pt 2):186-192.
  • 8Kautzner J,St'ovicek P,Anger Z,et al.Utility of short-term heart rate variability for prediction of sudden cardiac death after acute myocardial infarction.Acta Univ Palacki Olomuc Fac Med,1998,141:69-73.
  • 9Krumholz HM,Radford MJ,Wang Y,et al.Early β-blocker therapy for acute myocardial infarction in early patients.Ann Intern Med,1999,131(9):648-654.
  • 10刘国仗,胡大一,陶萍,诸骏仁,郭林妮,郭静萱,游凯.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11. 被引量:1439

共引文献248

同被引文献147

引证文献10

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部